Additionally, in vitro synergy of STAT3 inhibitors such as ruxolitinib, INCB16562, hydrocalamenene, genipin, and Iiariside II with bortezomib has been demonstrated in MM cells, via various mechanisms including JAK or SRC inhibition, or PIAS3, SHP1, and PTEN upregulation (Chong, Chng, and de Mel, 2019). The gene discussed is STAT3; the disease is Miyoshi myopathy.